Avid Bioservices Inc (CDMO)

[Protector]

sox, exactly my point.

Docetaxel does not outperform, for two decades people live between 3.4 and 10.4 months after a second line treatment with it depending on their stage and ECOG. It outperformed in the Docetaxel arm where patients progress FIRST then get 3rd line treatment. In the Doce+Bavi arm patients start progressing later and many of them will not yet have progression if Bvaituximab worked as expected.

Now people treated with it plus placebo suddenly dramatically outlive all those historical statistics and make a clinical trial fail by doing so because the drug under investigation, Bavituximab, must be compared with these exceptional and ABNORMAL Docetaxel results and can therefore not make its designed end-points.

Hence all those that are a little informed know bavituximab didn't fail but the clinical trial SUNRISE failed for the above reasons nothing to do with Bavituximab.

The value of PPHM comes from Bavituximab, its patents and an approval to sell. That last one is now delayed, and otherwise then when Bavituximab would have been at cause, ONLY DELAYED. Unfortunately for shareholders these delays are not welcome because we would like results yesterday rather then tomorrow.